The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer.

Latest advances in non-small cell lung cancer (NSCLC) therapies have revolutionized the treatment regimens utilized for NSCLCs with or without a driver mutation. Molecular targeted treatments such as tyrosine kinase inhibitors (TKIs) are utilized to prevent tumor progression and improve survival. Despite the great benefit of immunotherapy in NSCLC tumors with no driver mutation, the use of immune checkpoint inhibitors (ICIs) in NSCLC tumors harboring a driver mutation has been under debate.

Identifying violence against persons at a safety-net hospital: Evidence from the first 6 months of implementation.

Objective: To examine the prevalence and predictors of screening for violence against persons and victim service utilization within an integrated safety-net health system.

Study Setting: Emergency Department (ED) at Parkland Hospital-Dallas County's largest safety-net provider of services for minority and underinsured and uninsured patients.

Study Design: Prospective, longitudinal study during the first 6 months of a universal violence against persons screener.

Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project.

Background And Purpose: Only a small minority of acute stroke patients receive approved acute stroke therapy. We performed a community and professional behavioral intervention project to increase the proportion of stroke patients treated with approved acute stroke therapy.

Methods: This study used a quasi-experimental design.